According to a recent LinkedIn post from Axtria, Principal Vishal K. participated in a main-stage session at NEXT Pharma Summit 2026 alongside leaders from Sanofi, GSK, and Ipsen to discuss AI strategy in life sciences. The post highlights themes around build, buy, and partner decisions for AI capabilities.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests that hybrid models are emerging as the prevailing approach, with companies selectively combining internal development and external solutions. It also underscores that key assets such as data foundations, workflows, and orchestration are viewed as strategically important to keep in-house.
Axtria’s commentary points to scaling challenges in AI, including user adoption, trust, and meeting ROI expectations, which remain critical hurdles for pharma organizations. For investors, this focus indicates that AI deployments in life sciences may require longer adoption cycles and careful change management, potentially affecting timelines for realizing financial benefits.
Participation in such industry discussions may reinforce Axtria’s positioning as a data and analytics partner for pharma and life sciences companies pursuing AI-enabled transformation. If Axtria can help clients manage hybrid AI models and internal data ownership while demonstrating clear ROI, it could strengthen its competitive standing and support revenue growth opportunities in a rapidly evolving market.